Olaparib

Introduction Overview

Generic Name

olaparib

Brand Name

Lynparza

Dosage Form

Tablets (100 mg, 150 mg)

Drug Class

PARP inhibitors

Pharmacokinetics

Absorption:
Olaparib is well absorbed after oral administration, with peak plasma concentrations typically occurring within 1 to 3 hours post-dose. Its oral bioavailability supports convenient twice daily dosing. Food does not significantly affect the extent of absorption, though it may delay the time to reach peak concentration. This favorable absorption profile enables consistent systemic exposure across patients.

Distribution:
Olaparib exhibits a moderate volume of distribution, reflecting distribution into body tissues including tumors. It is approximately 82% bound to plasma proteins, primarily albumin, which affects free drug availability. Its ability to penetrate tissues facilitates targeted activity against malignant cells, especially those expressing DNA repair deficiencies. Distribution is not extensively altered by patient age or gender.

Metabolism:
Olaparib is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4/5. This metabolic pathway leads to the generation of several inactive metabolites. Concomitant administration of CYP3A inhibitors or inducers significantly influences olaparib plasma concentrations, necessitating dose adjustments to avoid toxicity or loss of efficacy. Metabolism is a critical determinant of the drug's pharmacokinetic variability.

Elimination:
Olaparib and its metabolites are eliminated predominantly through feces (~44%) and urine (~42%). The terminal half-life is approximately 12 hours, supporting its twice-daily dosing regimen. Renal impairment can reduce clearance moderately, and dose modifications may be required based on renal function. Hepatic impairment can also influence olaparib exposure due to its metabolism pathway. Overall, the elimination processes ensure steady drug levels with careful monitoring in special populations.

Dosage Forms

Available Dosage Forms:
- Oral Tablets available in 100 mg and 150 mg strengths.

Dosages for Adults and Adolescents:
- The standard adult dose is 300 mg (two 150 mg tablets) orally twice daily, approximately 12 hours apart.
- Dosing adjustments are recommended for patients with moderate renal impairment (dose reduction advised).
- Tablets must be swallowed whole; crushing, chewing, or breaking tablets is not recommended.

Specific Patient Populations:
- Patients with germline or somatic BRCA-mutated advanced cancers are dosed according to specific FDA-approved indications.
- Dose modifications may be necessary for patients with moderate to severe hepatic or renal impairment.
- The drug is contraindicated in pregnancy, and strict contraceptive measures are mandated during treatment and for months after cessation.
- Elderly patients require no initial dose adjustments but should be monitored for tolerability.
- Pediatric use is not established and thus not recommended.

Clinical guidelines emphasize adherence to genetic testing before initiating olaparib to confirm appropriate patient selection based on mutation status and companion diagnostic results.

Mechanism Of Action

Olaparib is a potent targeted inhibitor of the poly (ADP-ribose) polymerase (PARP) family of enzymes, primarily PARP1 and PARP2. PARP enzymes play a critical role in the repair of single-strand DNA breaks through the base excision repair pathway. By inhibiting PARP activity, olaparib promotes the accumulation of single-strand breaks, which during DNA replication can convert into lethal double-strand breaks.

Cancer cells that harbor deficiencies in homologous recombination repair (HRR) mechanisms, such as those with BRCA1 or BRCA2 mutations, rely heavily on PARP-mediated repair pathways for survival. Olaparib exploits this synthetic lethality by selectively killing tumor cells that lack efficient homologous recombination repair, inducing apoptosis and impairing tumor growth while sparing normal cells with intact DNA repair.

Biochemically, olaparib binds to the catalytic domain of PARP enzymes, preventing PARylation and trapping PARP-DNA complexes at sites of damage. This trapping exacerbates DNA damage beyond repair threshold in susceptible cancer cells. Clinical studies have demonstrated olaparib's efficacy correlates with the genetic profile of tumors, confirming the critical role of DNA repair pathways in its mechanism.

Comparatively, olaparib is among the first approved PARP inhibitors with a well-characterized profile, differing slightly in PARP trapping potency and selectivity from other agents such as niraparib and rucaparib. Ongoing research continues to elucidate combinational strategies and biomarker-driven applications to expand olaparib's therapeutic potential in oncology.

Pharmacological Actions

Inhibition of poly (ADP-ribose) polymerase (PARP) enzymes, blocking DNA single-strand break repair.
Induction of synthetic lethality in cancer cells with deficient homologous recombination repair (e.g., BRCA mutations).
Trapping PARP-DNA complexes, leading to accumulation of DNA damage and cell death.
Selective cytotoxicity toward tumor cells harboring genetic DNA repair abnormalities.
Modulation of DNA damage response pathways, impairing cancer cell proliferation.
Synergistic action with platinum-based chemotherapies through enhanced DNA crosslinking damage.
Potential immunomodulatory effects through increased tumor mutational burden.
Prolongation of progression-free survival in treated malignancies.
Dose-dependent pharmacodynamic effects aligning with efficacy and toxicity profiles.
Interference with tumor cell repair enhances susceptibility to apoptosis.
Facilitation of maintenance therapy post-response to chemotherapy to delay progression.
Targeted mechanism reduces systemic toxicity compared with cytotoxic chemotherapies.
Exploitation of tumor-specific genetic vulnerabilities for precision oncology.
Capability to cross cell membranes and distribute systemically to reach tumor sites.
Capability to reduce tumor burden in advanced or metastatic malignancies.

Therapeutic Or Clinical Uses

First-line maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutations following response to platinum-based chemotherapy.
Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy.
In combination with bevacizumab for first-line maintenance treatment in HRD-positive advanced ovarian cancers.
Adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer following neoadjuvant or adjuvant chemotherapy.
Treatment of germline BRCA-mutated HER2-negative metastatic breast cancer patients previously treated with chemotherapy.
First-line maintenance treatment of metastatic pancreatic adenocarcinoma with deleterious or suspected deleterious germline BRCA mutations following response to platinum-based chemotherapy.
Combination therapy with abiraterone and prednisone or prednisolone for deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
Treatment of HRR gene-mutated metastatic castration-resistant prostate cancer in patients progressing after enzalutamide or abiraterone therapy.
Indicated for patients selected based on FDA-approved companion diagnostic tests confirming appropriate genetic mutations or status.
Delays disease progression and extends progression-free survival in selected advanced or metastatic cancers.
Used as maintenance therapy to prolong remission duration post-chemotherapy response.
Targeted approach based on tumor genetic profiling in breast, ovarian, pancreatic, and prostate cancers.
Supports personalized medicine strategies in oncology.
May be used in patients with hormone receptor-positive breast cancer who have exhausted endocrine therapy options.
Enhances clinical outcomes in malignancies with DNA repair pathway abnormalities.

Side Or Adverse Effects

Anemia, neutropenia, and thrombocytopenia resulting in low blood cell counts.
Gastrointestinal symptoms including nausea, vomiting, diarrhea, heartburn, and indigestion.
Loss of appetite leading to potential weight loss during prolonged therapy.
Fatigue, dizziness, headaches, and general weakness impacting patient quality of life.
Respiratory symptoms such as cough and shortness of breath.
Altered taste sensation affecting food intake and nutrition.
Increased susceptibility to infections including serious and potentially fatal infections.
Allergic reactions including hives, facial or throat swelling, and difficulty breathing.
Potential development of blood clots (venous thromboembolism) especially when combined with GnRH therapy.
Serious pulmonary adverse events including pneumonitis, characterized by chest pain, wheezing, or new/worsening cough.
Bruising and unusual bleeding tendencies due to cytopenias.
Mouth and skin sores as manifestations of cytotoxic effects.
Possible weight loss linked with systemic side effects.
Delayed wound healing or complications with concurrent cancer therapies.
Potential for treatment interruptions or dose modifications due to side effect severity.

Precautions

Regular monitoring of blood counts is necessary due to risk of cytopenias and infection susceptibility.
Avoidance of grapefruit and Seville orange products to prevent CYP3A-mediated drug interactions.
Pregnant women should not take olaparib due to teratogenic risk; effective contraception required.
Male patients should use contraception during treatment and for three months post therapy due to potential reproductive risks.
Patients with pre-existing lung or kidney disease require cautious use and close monitoring.
Inform healthcare providers of all concomitant medications including over-the-counter and herbal supplements due to interaction potential.
Frequent clinical evaluation for signs of infection, bleeding, or thromboembolism is mandated.
Caution advised in patients receiving gonadotropin-releasing hormone agonists due to increased thrombotic risk.
Avoid breastfeeding during treatment and for at least one month following discontinuation.
Patients should report new respiratory symptoms promptly to address possible severe lung toxicity.
Dose adjustments may be necessary based on renal or hepatic function assessments.
Use in elderly patients requires monitoring for tolerability but no routine dose adjustment necessary.
Education on the importance of adherence to dosing schedule to maintain therapeutic drug levels.
Patients should be advised to not crush, chew or break tablets to ensure proper absorption.
Clinicians should consider genetic testing results carefully to confirm eligibility and expected benefit.

Warnings

Olaparib significantly affects the immune system, increasing vulnerability to serious, potentially fatal infections.
Patients should undergo regular blood testing, including weekly or monthly complete blood counts to monitor for cytopenias.
Concomitant use with gonadotropin-releasing hormone (GnRH) medicines may increase the risk of thromboembolic events such as deep vein thrombosis or pulmonary embolism.
Serious lung complications, including pneumonitis and interstitial lung disease, may occur; urgent evaluation is warranted for respiratory symptoms such as chest pain, wheezing, or shortness of breath.
Potential for delayed cancer treatment dosing schedules due to adverse hematologic or infectious toxicities.
Patients must be warned against pregnancy during and after treatment due to teratogenicity and fetal harm.
Medications affecting CYP3A enzymes may alter olaparib concentrations, necessitating dose adjustments or avoidance.
Allergic reactions including anaphylaxis can occur; emergency interventions should be accessible.
Patients should avoid grapefruit and related citrus products to reduce risk of adverse drug effects.
Drug overdose can be life-threatening; immediate medical attention is advised if overdose is suspected.
Potential risk of secondary malignancies, although rare, may be associated with long-term PARP inhibitor use.
Close monitoring for unusual bleeding or bruising is essential given thrombocytopenic risk.
Use with caution in patients with pre-existing cardiac or pulmonary disease due to additional risks.
Patients should be educated on early symptom recognition to prevent severe complications.
Treatment should be initiated and monitored by oncology specialists experienced in managing targeted therapies.

Contraindication

Known hypersensitivity or allergy to olaparib or any excipients contained in the dosage form.
Pregnancy due to teratogenic effects and risk of fetal harm.
Lactation period during olaparib therapy and for at least one month after discontinuation.
Patients with severe uncontrolled infections prior to initiation of therapy.
Concurrent use with strong CYP3A inducers unless dose adjustments are feasible and safe.
Known severe hepatic impairment without ability to monitor and adjust dosing accordingly.
Severe renal impairment without availability of appropriate dosing modifications and monitoring.
Patients unable to swallow tablets whole due to inability to maintain bioavailability.
History of severe thromboembolic events without adequate prophylaxis or management.
Concurrent participation in other investigational studies with conflicting therapies.
Presence of non-BRCA related cancers for which olaparib is not indicated.
Uncorrected bone marrow suppression or cytopenias prior to therapy commencement.
Known hypersensitivity to polysorbates or other tablet excipients causing reactions.
Severe pulmonary disease with active symptoms contraindicating olaparib use.
All patients must be screened with FDA-approved companion diagnostic tests to confirm mutation status to justify treatment initiation.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) can significantly increase olaparib plasma concentrations, heightening toxicity risk; dose adjustments required.
CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's Wort) reduce olaparib efficacy by lowering plasma levels; concomitant use should be avoided or dosing modified.
Concomitant administration with gonadotropin-releasing hormone agonists may elevate risk of venous thromboembolism.
Drugs affecting bone marrow function (e.g., chemotherapy, myelosuppressive agents) may potentiate cytopenias when combined with olaparib.
Anticoagulants and antiplatelet agents may increase bleeding risk during olaparib therapy.
Avoid grapefruit and Seville orange products which may inhibit CYP3A4 and increase olaparib exposure.
Potential interaction with P-glycoprotein substrates leading to altered pharmacokinetics.
Concomitant use with other PARP inhibitors or DNA-damaging agents can enhance toxicity and requires close monitoring.
Drugs that cause QT prolongation need cautious use as olaparib may exacerbate cardiac risks.
Interactions with hormonal therapies may modulate efficacy in hormone receptor-positive breast cancer patients.
Effect on efficacy of immunotherapies when combined necessitates careful clinical assessment.
Herbal supplements with CYP enzyme modulation properties may unpredictably alter olaparib levels.
Possible alterations in efficacy or toxicity when combined with bevacizumab or other targeted agents.
Olaparib may impact metabolism of other CYP3A substrates.
Co-administration with strong CYP3A modulators requires dose windowing and pharmacovigilance.

Preparations Of The Drug

Lynparza tablets formulated as immediate-release oral tablets available in 100 mg and 150 mg strengths.
Inactive ingredients include copovidone, mannitol, colloidal silicon dioxide, and sodium stearyl fumarate to ensure tablet stability and bioavailability.
Tablet coatings contain hypromellose, polyethylene glycol 400, titanium dioxide, ferric oxide yellow, and ferrosoferric oxide (150 mg tablets only) for identification and protection.
Manufactured to maintain product potency, stability, and consistency under ambient storage conditions.
Supplied in original bottles to protect from moisture and heat to preserve drug integrity.
Distributed by AstraZeneca Pharmaceuticals LP with adherence to regulatory quality standards.
Packaging designed to provide patient safety and compliance, including clear labeling for dosage strength.
Formulation optimized for twice-daily oral dosing with minimal food effect.
Excipients selected to minimize potential for hypersensitivity and gastrointestinal irritation.
Storage instructions specify room temperature maintenance between 20°C to 25°C (68°F to 77°F).
Bottles equipped with child-resistant caps to prevent accidental ingestion.
Tablets are non-chewable and should be swallowed whole to ensure proper absorption.
Developed to meet FDA requirements with established stability profiles for shelf-life.
Manufacturing processes comply with good manufacturing practices (GMP) focusing on purity and consistency.
Patient information leaflets accompany packaging to educate on proper use and safety.